Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: A process for preparing a compound of formula (I) ##STR1## wherein R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX4 is --OH, fluorine or --O--SO.sub.2 R6 where R6 is methyl, trifluoromethyl, phenyl or p-methylphenyl which comprises contacting of a compound of formula (III) ##STR2## where R2 is C.sub.1-4 alkyl; and R and X4 have the above mentioned meanings, with a strong base selected from the group consisting of alkali earth metal alcoholates, alkaline earth metal alcoholates, and tertiary amines in an aprotic solvent, to obtain the compound of formula (I).

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.3, R.sub.4, R.sub.11, and c are as set forth herein are described. These compounds are useful as agents for the treatment of mammals infected with herpes group virus. Certain of these compounds are useful as antitumor agents.

Abstract: A combination of a pharmacologically active compound and a water soluble monoester of a saturated or unsaturated (C.sub.6-18) fatty acid and a polyol, especially a saccharide, particularly as a solid solution of the active compound in the monoester.The solid solution is especially suitable for substantially water insoluble active compounds, particularly such polypeptides, e.g. ciclosporins and is in all desirable weight ratios miscible with water.The invention also, in particular, provides pharmaceutical compositions comprising a cyclosporin as active ingredient together with a fatty acid saccharide monoester.

Abstract: The invention provides diet supplements for pre-operative treatment of patients due for surgery.

Abstract: A dietary composition comprising, based on total caloric content of the composition,a) a carbohydrate component which comprises from 50 to 65% of the total caloric content;b) a lipid component which comprises from 20 to 35% of the total caloric content; andc) an amino acid component which comprises from 10 to 20% of the total caloric content and which comprises specified amino acids and amounts thereof is useful providing nutrition to human adolescents.

Abstract: Compounds of the formula ##STR1## and salts thereof, wherein eachR.sub.1 is independently hydrogen or C.sub.1-4 alkyl, andR.sub.2 is hydrogen; C.sub.1-6 alkyl; C.sub.2-4 alkenyl; C.sub.2-4 alkynyl; cyclohexyl; phenyl; phenyl substituted by 1 to 3 substituents selected from halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, --SO.sub.3 H and --COOH; phenyl (C.sub.1-4 alkyl); phenyl(C.sub.1-4 alkyl) the phenyl ring of which is substituted by 1 to 3 substituents selected from halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, --SO.sub.3 H and --COOH; or --W--Y,whereinW is linear or branched C.sub.1-6 alkylene, andY is --COOH, --COOC.sub.1-4 alkyl, --SO.sub.3 H, --OSO.sub.3 H, hydroxy, cyano, C.sub.1-4 alkoxy, --NH.sub.

Abstract: An improved process for producing a water-soluble polymyxin B/dextran conjugate comprises the step of reacting polymyxin B or pharmaceutically acceptable salt thereof with dextran in an aqueous media at a pH of about 9.3 to 10.

Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Abstract: Compounds of the formula ##STR1## wherein R, R.sub.1 and R.sub.2 are as defined in the specification and R.sub.3 is amino or --N.dbd.N--K, wherein K is a coupling component radical. The compounds wherein R.sub.3 is --N.dbd.N--K are useful as disperse dyes, and those wherein it is amino are useful as intermediates in the synthesis of those wherein it is --N.dbd.N--K.

Abstract: A process for providing a variety of light to medium colors of anodized aluminum or aluminum alloy which comprises the steps of anodizing an aluminum or aluminum alloy workpiece in an aqueous strong acid electrolyte solution such as a sulfuric acid solution by application of direct current at a current density of 5 to about 25 amperes per square foot and a temperature of from 55.degree. F. to 90.degree. F. to form on the workpiece a porous anodic oxide film having a thickness of at least about 3 microns; subjecting the resulting anodized workpiece to alternating current at a voltage of about 5 to about 25 volts for about 1 to 25 minutes in an aqueous strong acid electrolyte solution such as a sulfuric acid solution comprising about 1 to 15 volume percent of an organic carboxylic acid containing at least one reactive group in the alpha-position, wherein said reactive group is a hydroxy, amino, keto or carboxyl group; and electrolytically coloring the workpiece.

Abstract: A process for preparing carboxylates of polyoxyalkylene siloxanes and -amines, alkylpolyoxyalkylenes, polyoxyalkylene block polymers, alkylamidepolyoxyalkylenes and alkylpolyglucosides comprising subjecting a primary hydroxyl group-containing polyoxyalkylene compound or alkylpolyglucoside to mild oxidiation. The invention also relates to the novel polyoxyalkylene amine and alkylamidepolyoxyalkylene carboxylates prepared by the process.

Abstract: A process for preparing carboxylates of polyoxyalkylene siloxanes and -amines, alkylpolyoxyalkylenes, polyoxyalkylene block polymers, alkylamidepolyoxyalkylenes and alkylpolyglucosides comprising subjecting a primary hydroxyl group-containing polyoxyalkylene compound or alkylpolyglucoside to mild oxidiation. The invention also relates to the novel polyoxyalkylene amine and alkylamidepolyoxyalkylene carboxylates prepared by the process.

Abstract: Compounds of the formula ##STR1## iron complexes thereof and mixtures of such iron complexes, wherein D is a monocyclic or bicyclic aromatic diazo component radical of the benzene series containing one --SO.sub.3 M group or is ##STR2## R.sub.1 is hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, chloro or C.sub.1-2 alkyl,wherein R' is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or ##STR3## R" is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl or methoxy(C.sub.2-4 alkyl), or--NR'R" is a saturated 5- or 6-membered ring,R.sub.5 is hydrogen, chloro or C.sub.1-2 alkyl, andX is hydrogen or hydroxy,wherein each R.sub.2 is independently hydrogen, chloro, hydroxy, C.sub.1-2 alkyl, C.sub.1-2 alkoxy or --SO.sub.2 NR.sub.o R.sub.o, andeach R.sub.3 is independently hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, --COOM, trifluoromethyl or --NR"'R"",wherein each R"' and R"" is independently C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or carbamoyl(C.sub.

Abstract: The invention relates to mixtures comprisingone or more phthalocyanine dyes of formula I ##STR1## wherein CuPc is the radical of a Cu-phthalocyanine dye,A is selected from the group consisting of optionally substituted, linear or branched C.sub.2 -C.sub.6 -alkylene groups,R.sub.1 and R.sub.2 independently of one another, are selected from the group consisting of hydrogen or optionally substituted, linear or branched C.sub.1 -C.sub.6 -alkyl,M is selected from the group consisting of hydrogen, lithium, sodium, potassium, ammonium or substituted ammonium,x and y is 1 to 3, with the provision that the sum of x+y is 3 to 4, and; one or more azo dyes of formula II: ##STR2## wherein R.sub.

Abstract: The invention discloses compounds of formula I ##STR1## wherein X is oxygen or sulfur,R is hydrogen, chlorine or fluorine,R.sub.1 is fluorine, chlorine, bromine, cyano or methyl,R.sub.2 is halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylcarbonyloxy, C.sub.3-6 cycloalkoxy, C.sub.3-6 alkynyloxy, C.sub.3-6 alkenyloxy, --COOH, --CO--R.sub.3, --CO--NR.sub.4 R.sub.5, --NR.sub.6 R.sub.7, C.sub.2-6 alkenyl, N-pyrrolyl, 2-oxo-3-tetrahydrofuranyl or isC.sub.1-6 alkyl substituted with halogen, COOH, --CO--R.sub.3, --CO--NR.sub.8 R.sub.9, .dbd.N--OH, .dbd.N--C.sub.1-4 alkoxy, --O--CO--R.sub.3 or --O--C.sub.2-3 alkylene-O--; or isC.sub.2-6 alkenyl substituted with halogen, COOH, --CO--R.sub.3, --CO--NR.sub.8 R.sub.9 or C.sub.1-4 alkoxy; or isC.sub.1-6 alkoxy substituted with cyano, --CO--R.sub.3, C.sub.1-4 alkoxy, C.sub.3-6 cycloalkyl, oxiranyl, orC.sub.1-4 alkoxy or halogen; or isC.sub.3-6 alkenyloxy substituted by C.sub.2-5 alkynyl;R.sub.3 is C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 cyanoalkyl, C.sub.

Abstract: Mixtures of certain triazole fungicides (component I) and 4,6-dimethyl-N-phenyl-2-pyrimidinamine (component II) achieve synergistically enhanced activity against fungus infestation. Components I and II can also be applied to plant crops individually, one immediately after the other.

Abstract: Composition comprising glycine and/or other amino acids are useful in treating or minimizing the effects of endotoxemia, hypoxia-reperfusion injury and infection.

Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.